TITLE:
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

CONDITION:
Prostatic Neoplasms

INTERVENTION:
ZD4054 10 mg

SUMMARY:

      The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in
      men with prostate cancer
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Male
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Men 18 years & older

          -  Confirmed diagnosis of prostate cancer with bone metastases

        Exclusion Criteria:

          -  No more than 2 prior chemotherapy regimens

          -  No radiation, chemotherapy or bisphosphonates in the past 4 weeks
      
